Quality Comes First

          

APAC MARKETS

We seek to advance highly specialised and scientifically valuable fields to elevate the standard of healthcare.

Discover more about Menarini Group

For over 30 years, Menarini has been driving research and development to deliver innovative and effective medicines and healthcare solutions for patients affected by serious health conditions.

Gain a single point of entry to all major APAC markets with a direct presence in 13 key markets.

Sharing your partnering idea

Leverage our omni-channel approach to grow your brand across Asia Pacific.

MARKETS

The healthcare sector in Asia Pacific is rapidly growing. As part of the world’s leading Italian biopharmaceutical company, Menarini AP has a strong presence in 13 key markets across the region.

As a partner of choice for numerous global healthcare companies, we engage in the entire pharmaceutical development lifecycle to tap growth opportunities and grow their brand footprint. In doing so, we also support healthcare professionals and patients with quality medical products and technology to raise standards and invigorate lives for tomorrow.

Our APAC Headquarters

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

2012

2012

  • 2012 - 12 - 06

    Invida changes name to Menarini Asia-Pacific

    Singapore - 7th December 2012- Invida Holdings Private Limited, the leading biopharmaceutical commercialization company in Asia-Pacific, is pleased to announce a name change to A. Menarini Asia-Pacific Holdings Pte. Ltd. ("Menarini Asia-Pacific") effective immediately. The brand transformation reflects its alignment with parent, Menarini Group, and allows for the promotion of a single, unified brand in the global marketplace. The name change will also progressively take place across its other offices within the region in 2013.
  • 2012 - 10 - 30

    Menarini Group and Oxford BioTherapeutics, UK, sign strategic collaboration for clinical development and manufacture of novel antibody-based cancer drugs.

    Oxford, UK and Florence, Italy - 29th October 2012 - Menarini and Oxford BioTherapeutics (OBT) today announce a major innovative and strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer. The agreement covers five of OBT's antibody and antibody drug conjugate (ADC) programs, each of which addresses a different cancer indication via a different novel oncology target.
  • 2012 - 10 - 10

    Almirall grants Invida commercial rights for Aclidinium in Australia and New Zealand

    Barcelona and Singapore - 10th October 2012. Almirall (ALM:MC) and Invida Holdings Private Limited, a member of the Menarini Group, are pleased to announce that Almirall has granted Invida commercial rights for Aclidinium in Australia and New Zealand for the treatment of COPD. Financial details of the agreement have not been disclosed. The agreement includes both Aclidinium monotherapy and its combination with Formoterol.
  • 2012 - 04 - 27

    Faes Farma and Invida signs on exclusive long-term agreement to commercialize Bilastine

    FAES FARMA and INVIDA (a MENARINI Company) announce agreement to commercialize bilastine in 17 markets in Asia-Pacific Spain and Singapore [27] April 2012 – FAES FARMA, a leading Spanish pharmaceutical group dedicated to research, development, manufacturing and marketing of pharmaceuticals, and INVIDA Holdings Private Limited, a Member of the MENARINI Group and leading specialty biopharmaceutical company focused on the Asia-Pacific region, are pleased to announce the signing of an exclusive long-term agreement to commercialize bilastine in 17 markets in Asia-Pacific.